New Drug Trial Aims To Prevent Alzheimer’s Before It Starts
Researchers will test an experimental drug that could prevent Alzheimer’s disease in people who are genetically slated to develop Alzheimer's disease but have yet to exhibit symptoms.
The PatientCrossroads registry platform is the backbone of this innovative prevention trial. The goal of the registry is to registry 100,000 participants in the first year growing to 250,000 patients after two years. The registry will be personalized based user medical history and provide researchers with ready access to willing participants for studies that could lead to treatments for Alzheimer's.